# Fed Bioequivalence Study of Fenofibric Acid Versus TriCor® (Fenofibrate)

> **NCT00960687** · PHASE1 · COMPLETED · sponsor: **Mutual Pharmaceutical Company, Inc.** · enrollment: 54 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Fenofibric Acid (Fibricor™) 105 mg Tablet
- **DRUG:** Fenofibrate (Tricor®) 145 mg Tablet

## Key facts

- **NCT ID:** NCT00960687
- **Lead sponsor:** Mutual Pharmaceutical Company, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2009-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00960687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00960687, "Fed Bioequivalence Study of Fenofibric Acid Versus TriCor® (Fenofibrate)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00960687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*